Assessing the stakeholder landscape and stance point on genomic and personalized medicine

The pace of discoveries and advances in genomic research to individualize the health-care decision-making process is not reflected in the pace of their translation and incorporation into day-to-day clinical medicine. One of the major obstacles is the poor understanding of the policies, opinions, and overall landscape of the key stakeholders involved in this translation process to assess of the policy’s content, the major players, their power and policy positions, their interests and networks, and coalitions that connect them. Such an effort would contribute in establishing and/or adjusting the necessary policy measures that will expedite the adoption of genomics into the mainstream medical interventions. This chapter aims to provide an overview of the process for assessing the views and opinions of stakeholders toward pharmacogenomics and genomic medicine and an example of implementing such an approach in a health-care environment.